CONMED Corporation (NASDAQ: CNMD) today announced that its CONMED
Endoscopic Technologies business unit will formally launch multiple
new medical devices at the Digestive Disease Week (DDW@) conference in
San Diego, CA on May 20-22, 2012, as well as the Society for
Gastroenterology Nurses and Associates (SGNA) Annual Course in
Phoenix, AZ on May 18-23, 2012.
"CONMED has been energizing therapeutic endoscopy and provided
important medical solutions to the global GI community for over 20
years," said Mark Donovan, Vice President of the CONMED Endoscopic
Technologies business unit. "The launch of six new, important products
at DDW and SGNA this week underscores our continued commitment to
delivering critical advancements for GI physicians, and their
The following products are being launched at DDW/SGNA:
ClearView?EUS FNA System - CONMED Endoscopic Technologies ClearView?
Endoscopic Ultrasound (EUS) needle features Twist Lock Technology
(TLT?), which allows the physician to adjust the sheath and needle
piston with one hand, while current technology requires thumb screws
to secure the pistons. ClearView's laser-treated needle tip also
provides enhanced visualization for the physician. CONMED Endoscopic
Technologies offers a full range of EUS needles -- 19g, 22g and 25g.
EUS is one of the fastest growing segments in the GI market.
BiCap III? - BiCap III? Electrosurgical Unit (ESU) incorporates
CONMED's Dynamic Response technology, which reacts to different tissue
impedances in less than one millisecond, ensuring a consistent
delivery of power and clinical effect while minimizing surrounding
tissue damage. This GI-focused unit brings modern day ESU Technology
into the GI Lab in an economical and user-friendly format.
EnTake?PEG - CONMED has extended its highly sought after EnTake?
gastrostomy product line to include initial placement kits without
drugs. Facilities often already have lidocaine on hand and, therefore,
have no need for it to be included in the kits. Without the lidocaine,
EnTake? ND offers an economical solution, as well as longer shelf
ClearGuard? - The ClearGuard? Biopsy Valve is designed to help reduce
cross-contamination from bodily fluids and eliminates the need for
reprocessing valves. ClearGuard helps maintain luminal insufflations
while restricting backflow during a procedure.
Optimizer?Polyp Trap - CONMED Endoscopic Technologies has extended its
Optimizer Polyp Trap line, another highly sought after product. The
Optimizer Polyp Trap is renowned for its versatility with four
independent, selectable trap chambers, along with four multiple direct
bypass channels. Each chamber has visual markers for identification.
Optimizer Polyp Trap is individually packaged for single patient use
to reduce the risk of cross-contamination.
Enteroscope SpiderNet? - CONMED Endoscopic Technologies has extended
its SpiderNet line with the introduction of the enteroscopic version.
SpiderNet's pouch delicately closes around the specimen during
retraction, reducing the risk of loss or damage. When wet, the net
material becomes translucent for enhanced endoscopic visibility. An
atraumatic net configuration, SpiderNet minimizes the potential for
minced specimen or crushed artifact.
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and
monitoring. The Company's products serve the clinical areas of
arthroscopy, powered surgical instruments, electrosurgery, cardiac
monitoring disposables, endosurgery and endoscopic technologies. They
are used by surgeons and physicians in a variety of specialties
including orthopedics, general surgery, gynecology, neurosurgery, and
gastroenterology. Headquartered in Utica, New York, the Company's
3,400 employees distribute its products worldwide from several
Forward Looking Information
This press release contains forward-looking statements based on
certain assumptions and contingencies that involve risks and
uncertainties. The forward-looking statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995 and relate to the Company's performance on a going-forward
basis. The forward-looking statements in this press release involve
risks and uncertainties which could cause actual results, performance
or trends, to differ materially from those expressed in the
forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the
forward-looking statements will actually occur or prove to be correct.
In addition to general industry and economic conditions, factors that
could cause actual results to differ materially from those discussed
in the forward-looking statements in this press release include, but
are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks
relating to forward-looking statements discussed in the Company's
Annual Report on Form 10-K for the fiscal year ended December 31,
2011; (iii) cyclical purchasing patterns from customers, end-users and
dealers; (iv) timely release of new products, and acceptance of such
new products by the market; (v) the introduction of new products by
competitors and other competitive responses; (vi) the possibility that
any new acquisition or other transaction may require the Company to
reconsider its financial assumptions and goals/targets; (vii)
increasing costs for raw material, transportation of litigation;
(viii) the risk of a lack of allograft tissues due to reduced
donations of such tissues or due to tissues not meeting the
appropriate high standards for screening and/or processing of such
tissues; and/or (ix) the Company's ability to devise and execute
strategies to respond to market conditions.